CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA)...
CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis
Eisai’s Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer...
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulation and evaluates further...
Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulation and evaluates further product improvement options
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3
